Richard Rupp, MD

Projects

Projects per year 2007 2017 2018 2027

• 32 Active
• 94 Completed

Projects per year

Search results

• Active

  A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults

  Rupp, R.

  4/1/22 → 3/31/27

  Project: Other project

• Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants (short title, COVID-19 Adaptive Variant Immunologic Landscape Trial (COVAIL Trial)

  Rupp, R.

  3/31/22 → 12/31/23

  Project: Other project

• A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

  Rupp, R.

  2/14/22 → 2/13/27

  Project: Other project

• A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  Rupp, R.

  2/11/22 → 2/10/27

  Project: Other project

• A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh

  Rupp, R.

  11/12/21 → 11/11/26

  Project: Other project

• A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age

  Rupp, R.

  10/19/21 → 10/18/26

  Project: Other project

• A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines

  Rupp, R.

  7/14/21 → 11/30/22

  Project: Other project

• PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTH

  Rupp, R.

  Pfizer, Inc.

  3/29/21 → 3/28/26

  Project: Other project

• A Phase 3 Randomized, Observer-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Adults 18 through 55 years of Age.

  Rupp, R.

  Pfizer, Inc.

  3/11/21 → 3/10/25

  Project: Other project

• A Phase 3 Randomized, Observer-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Adults 18 through 55 years of Age.

  Rupp, R.

  3/11/21 → 3/10/25

  Project: Other project

• A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

  Rupp, R.

  Merck Sharp & Dohme Corporation

  1/29/21 → 1/28/26

  Project: Other project

• A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE

  Rupp, R.

  Pfizer, Inc.

  1/4/21 → 1/3/23

  Project: Other project

• A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen

  Rupp, R.

  Merck Sharp & Dohme Corporation

  12/22/20 → 12/21/25

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU)- COVID Supplement

  Rupp, R.

  7/13/20 → 11/30/22

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU)- COVID Supplement

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  7/13/20 → 11/30/22

  Project: Other project

• A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

  Rupp, R.

  Pfizer, Inc.

  6/19/20 → 6/18/24

  Project: Other project

• A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

  Rupp, R.

  6/19/20 → 6/18/24

  Project: Other project

• A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

  Rupp, R.

  Astellas Pharma Global Development Inc

  6/19/20 → 6/18/23

  Project: Other project

• A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

  Rupp, R.

  6/19/20 → 6/18/23

  Project: Other project

• A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and

  Rupp, R.

  2/12/20 → 2/11/25

  Project: Other project

• A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and

  Rupp, R.

  2/12/20 → 2/11/25

  Project: Other project

• A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo- controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persisten

  Rupp, R.

  12/12/19 → 12/11/23

  Project: Other project

• A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo- controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persisten

  Rupp, R.

  12/12/19 → 12/11/23

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 -dose Regimen of V114 in Healthy Infants (PNEU-PED)

  Rupp, R.

  4/25/19 → 4/24/23

  Project: Other project

• Comprehensive Analysis of CMV-specific T cells in Human Subjects Receiving a Replication-defective Human Cytomegalovirus Vaccine

  Rupp, R.

  8/28/18 → 8/27/22

  Project: Other project

• A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R.

  7/5/18 → 7/4/23

  Project: Other project

• A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

  Rupp, R.

  7/2/18 → 7/1/23

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y

  Rupp, R.

  7/1/18 → 6/30/23

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 One Year Later in Healthy Adults 50 Years of Age or Older (PN

  Rupp, R.

  6/11/18 → 6/10/23

  Project: Other project

• A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when administered concomitantly with routine pe

  Rupp, R.

  5/2/18 → 5/1/23

  Project: Other project

• Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35

  Rupp, R.

  4/24/18 → 4/23/23

  Project: Other project

• A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDEDS TUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER

  Rupp, R.

  2/7/17 → 2/6/23

  Project: Other project

• Completed

  IMPAACT Leadership Group-PTCL 03

  Rupp, R.

  12/1/20 → 11/30/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU)

  Rupp, R.

  3/13/20 → 11/30/20

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU)

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  3/13/20 → 11/30/20

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  Mapp Biopharmaceutical Inc

  6/27/19 → 6/30/21

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  6/27/19 → 6/30/21

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  6/27/19 → 6/30/21

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  6/27/19 → 6/30/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 -dose Regimen of V114 in Healthy Infants (PNEU-PED)

  Rupp, R.

  4/25/19 → 4/24/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13¿ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

  Rupp, R.

  9/14/18 → 9/13/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13¿ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

  Rupp, R.

  9/14/18 → 9/13/21

  Project: Other project

• Comprehensive Analysis of CMV-specific T cells in Human Subjects Receiving a Replication-defective Human Cytomegalovirus Vaccine

  Rupp, R.

  8/28/18 → 8/27/21

  Project: Other project

• A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Administered Concomitantly with Routine Vaccines to Heal

  Rupp, R.

  7/9/18 → 7/8/20

  Project: Other project

• A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Administered Concomitantly with Routine Vaccines to Heal

  Rupp, R.

  7/9/18 → 7/8/20

  Project: Other project

• A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R.

  7/5/18 → 7/4/21

  Project: Other project

• A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

  Rupp, R.

  7/2/18 → 7/1/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y

  Rupp, R.

  7/1/18 → 6/30/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 One Year Later in Healthy Adults 50 Years of Age or Older (PN

  Rupp, R.

  6/11/18 → 6/10/21

  Project: Other project

• A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when administered concomitantly with routine pe

  Rupp, R.

  5/2/18 → 5/1/21

  Project: Other project